Gilead's Simtuzumab Fails in Phase 2
The antibody, an inhibitor of the enzyme lysyl oxidase-like-2, combined with gemcitabine, did not have a significant effect on progression-free survival compared to the placebo with gemcitabine arm, in pancreatic cancer patients.
AMA Seeks EHR Upgrade
The American Medical Association has released a framework to improve usability of electronic health records so as to benefit the patients and providers.
Tens of Thousands at Risk of Losing ACA Insurance Coverage
The federal government will terminate health insurance coverage under the Affordable Care Act for 115,000 individuals who failed to prove they were United States citizens or legal immigrants. Furthermore, another 363,000 people could lose their financial aid because of income reporting discrepancies.
Gilead’s New Hepatitis C Drug Will Cost More
Despite the current high cost of Gilead Science’s hepatitis C drug, the next generation version will be even more expensive. However, the company also struck deals with generic drugmakers to bring the drug to developing countries.
To Treat or Not to Treat: The Overdiagnosis Debate
Rapid advances in detection technology, coupled with an increased awareness about screening, have ignited a debate on overdiagnosis and overtreatment of precancerous lesions. Should physicians use their discretion and implement a "wait-and-watch" approach?
PCORI Announces Pilot Projects Program Awards Recipients
The Patient-Centered Outcomes Research Institute (PCORI) has announced the approval of 50 research funding awards, totaling $30 million over two years, through its Pilot Projects Program, which will address a broad range of questions about methods for engaging patients in the health research and dissemination process.
CMS's Open Payments Database on Schedule for Launch
Despite reported glitches, CMS plans to launch the database that will provide information on payments for research, gifts, meals, or speaker fees received by providers and teaching hospitals from the pharmaceutical industry.